Success Metrics

Clinical Success Rate
96.4%

Based on 27 completed trials

Completion Rate
96%(27/28)
Active Trials
3(7%)
Results Posted
37%(10 trials)
Terminated
1(2%)

Phase Distribution

Ph not_applicable
20
47%
Ph phase_2
4
9%
Ph phase_4
8
19%
Ph phase_3
3
7%
Ph phase_1
4
9%
Ph early_phase_1
4
9%

Phase Distribution

8

Early Stage

4

Mid Stage

11

Late Stage

Phase Distribution43 total trials
Early Phase 1First-in-human
4(9.3%)
Phase 1Safety & dosage
4(9.3%)
Phase 2Efficacy & side effects
4(9.3%)
Phase 3Large-scale testing
3(7.0%)
Phase 4Post-market surveillance
8(18.6%)
N/ANon-phased studies
20(46.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

27 of 30 finished

Non-Completion Rate

10.0%

3 ended early

Currently Active

3

trials recruiting

Total Trials

43

all time

Status Distribution
Active(7)
Completed(27)
Terminated(3)
Other(6)

Detailed Status

Completed27
unknown5
Active, not recruiting3
Not yet recruiting2
Withdrawn2
Enrolling by invitation2

Development Timeline

Analytics

Development Status

Total Trials
43
Active
3
Success Rate
96.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (9.3%)
Phase 14 (9.3%)
Phase 24 (9.3%)
Phase 33 (7.0%)
Phase 48 (18.6%)
N/A20 (46.5%)

Trials by Status

not_yet_recruiting25%
unknown512%
withdrawn25%
terminated12%
active_not_recruiting37%
suspended12%
enrolling_by_invitation25%
completed2763%

Recent Activity

Clinical Trials (43)

Showing 20 of 43 trialsScroll for more
NCT07494084Phase 4

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

Not Yet Recruiting
NCT04895358Phase 3

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Active Not Recruiting
NCT02653092Not Applicable

Reprometabolic Syndrome Mediates Subfertility in Obesity

Active Not Recruiting
NCT05985135Not Applicable

Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus

Not Yet Recruiting
NCT07428512Not Applicable

Comparison of the Effectiveness of 5% and 10% Dextrose Treatments in Patients With Chronic Shoulder Pain: Ultrasound-Guided Perineural Injection

Completed
NCT05264727Phase 4

Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion

Active Not Recruiting
NCT06675708Not Applicable

Effectiveness of Creatine on Pain, Fatigue, and Muscle Architectural Variables in Patients Witg Fibromyalgia.

Enrolling By Invitation
NCT06635174Not Applicable

Efficacy of 50% Oral Dextrose As Pain Relief in Newborns Before Bladder Catheterization

Enrolling By Invitation
NCT03809546Early Phase 1

Individual Differences in Drug Response

Completed
NCT04020601Phase 2

The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane in Total Shoulder Arthroplasty

Terminated
NCT06294938Not Applicable

Glycemic Index of Cacao Fruit Pulp in Healthy, Human Subjects

Completed
NCT06222047Not Applicable

Pain and Comfort Level During Orogastric Catheter Insertion in Preterms

Completed
NCT02471690Phase 1

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

Completed
NCT04294966Early Phase 1

Age-Related Effects of THC

Completed
NCT05918146Phase 4

Dextrose Therapy on Physical Therapy in Subdeltoid Bursitis

Unknown
NCT03998709Phase 4

Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion

Withdrawn
NCT03411811Not Applicable

Ulnar Wrist Pain Treatment With Dextrose Prolotherapy

Unknown
NCT04821882Not Applicable

Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis

Completed
NCT04791202Phase 3

Hypertonic Dextrose Versus Corticosteroid Intra-Articular Injections for the Treatment of Trapeziometacarpal Arthritis

Unknown
NCT03170544Phase 1

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
43